一分钟看懂
这是一项关于恶性肿瘤的I 期 / II 期研究，登记的药物或干预包括MK-1084；Patritumab deruxtecan；Sacituzumab tirumotecan；Cetuximab；Rescue Medications，当前状态为招募中。登记地点显示中国广州、昆明有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
MK-1084；Patritumab deruxtecan；Sacituzumab tirumotecan；Cetuximab；Rescue Medications · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录6项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Guangdong Provincial People s Hospital ( Site 0300) · 广州
- Yunnan Province Cancer Hospital ( Site 0302) · 昆明
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- The main inclusion criteria include but are not limited to the following:
- * Has histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
- * Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene (KRAS) mutation of glycine to cysteine at codon 12 (G12C) mutations
- * Has documented disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy and platinum-based chemotherapy
- * Has provided tumor tissue for biomarker analysis from an archival sample or a newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
- * Participants with human immunodeficiency virus (HIV) infection must have well-controlled HIV on antiretroviral therapy (ART) per protocol
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07286149；登记信息更新于 2026-10-01；本站同步于 2026-10-08。